Crossmark

177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database

Crossref DOI link: https://doi.org/10.1007/s11255-025-04804-8

Published Online: 2025-09-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aijaz, Parisa

Eby, Ashley

Collins, Jennifer

Kamran, Amir
License Information

Text and Data Mining valid from 2025-09-24

Version of Record valid from 2025-09-24
More Information

Article History

Received: 13 May 2025

Accepted: 17 September 2025

First Online: 24 September 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below